Stock Analysis on Net
Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Amgen Inc., historical price multiples (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Price to earnings (P/E) 25.22 22.82 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Price to operating profit (P/OP) 19.30 16.84 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Price to sales (P/S) 6.08 5.02 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Price to book value (P/BV) 18.86 19.37 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The valuation profile exhibits significant volatility, particularly within earnings-based multiples and book value ratios, while sales-based valuation remained relatively stable over the observed period. A notable anomaly occurs in early 2024, characterized by a sharp spike in price-to-earnings and price-to-operating profit ratios, followed by a gradual reversion toward historical means.

Price to Earnings (P/E) Ratio
The P/E ratio maintained a range between 16.18 and 23.14 from March 2022 through December 2023. However, a substantial escalation is observed in the first half of 2024, peaking at 53.65 in June 2024. This period of expansion suggests either a significant contraction in net income or a rapid increase in market price. Following this peak, the ratio decelerated throughout 2024 and 2025, eventually stabilizing between 22.82 and 25.22 by mid-2026.
Price to Operating Profit (P/OP) Ratio
The P/OP trend closely mirrors the P/E trajectory, indicating that the valuation volatility was driven by factors affecting both the top-line operating performance and bottom-line net income. The ratio rose from a low of 13.40 in December 2022 to a peak of 27.68 in September 2024. A subsequent correction occurred, with the ratio settling into a range of 16.84 to 19.30 during the 2025-2026 period.
Price to Sales (P/S) Ratio
Compared to earnings and book value multiples, the P/S ratio demonstrated the highest degree of stability. Values fluctuated within a narrow band, generally between 4.57 and 6.08. The lack of extreme spikes during the early 2024 period—where P/E and P/OP peaked—suggests that the volatility in those ratios was likely due to fluctuations in profitability rather than a fundamental shift in how the market valued the company's revenue stream.
Price to Book Value (P/BV) Ratio
A precipitous decline in the P/BV ratio is evident at the start of the period, falling from an extreme high of 138.87 in March 2022 to 23.95 by March 2023. This drastic reduction suggests a significant change in the equity base, potentially due to an increase in retained earnings or a decrease in treasury stock. From 2023 through 2026, the ratio stabilized, oscillating between a low of 17.87 and a high of 33.25, indicating a more normalized relationship between market capitalization and book value.

Overall, the data indicates a transition from extreme book-value premiums in early 2022 to a period of heightened earnings-based valuation in 2024, concluding with a stabilization of all primary valuation metrics by mid-2026.

AI Ask an analyst for more



Price to Earnings (P/E)

Amgen Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 540,632,005 539,708,274 539,067,675 538,480,671 538,361,851 537,706,118 537,204,943 537,532,723 537,329,220 536,434,692 535,918,901 535,178,027 534,901,181 534,326,594 533,976,238 533,579,206 534,930,850 534,199,933
Selected Financial Data (US$)
Net income (loss) (in millions) 2,375 1,819 1,333 3,216 1,432 1,730 627 2,830 746 (113) 767 1,730 1,379 2,841 1,616 2,143 1,317 1,476
Earnings per share (EPS)2 16.17 14.45 14.30 13.01 12.29 11.03 7.61 7.87 5.83 7.01 12.53 14.14 14.92 14.82 12.27 12.81 12.29 10.71
Share price1, 3 407.83 329.82 369.19 319.86 284.67 281.22 291.16 320.16 312.50 311.29 290.07 255.70 243.28 239.74 240.00 269.04 246.25 238.13
Valuation Ratio
P/E ratio4 25.22 22.82 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 68.64 97.96 94.06 159.78 92.57 77.73 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64
Bristol-Myers Squibb Co. 14.27 17.01 17.30 15.38 17.46 18.29 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64
Danaher Corp. 31.43 37.32 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Eli Lilly & Co. 41.23 34.82 47.45 43.36 43.95 67.76 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29
Gilead Sciences Inc. 18.06 21.54 18.18 21.68 20.62 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25
Johnson & Johnson 29.70 25.87 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Merck & Co. Inc. 99.98 31.27 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Pfizer Inc. 33.42 20.12 19.83 14.06 13.09 17.22 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Regeneron Pharmaceuticals Inc. 17.56 16.27 18.19 15.03 13.29 13.65 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15
Thermo Fisher Scientific Inc. 30.48 25.46 28.82 32.45 26.56 24.55 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15
Vertex Pharmaceuticals Inc. 27.54 24.83 31.58 29.11 26.43 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
EPS = (Net income (loss)Q2 2026 + Net income (loss)Q1 2026 + Net income (loss)Q4 2025 + Net income (loss)Q3 2025) ÷ No. shares of common stock outstanding
= (2,375,000,000 + 1,819,000,000 + 1,333,000,000 + 3,216,000,000) ÷ 540,632,005 = 16.17

3 Closing price as at the filing date of Amgen Inc. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/E ratio = Share price ÷ EPS
= 407.83 ÷ 16.17 = 25.22

5 Click competitor name to see calculations.


The stock valuation metrics exhibit a period of relative stability followed by a phase of significant volatility and subsequent normalization between March 2022 and June 2026. While the share price demonstrates a long-term upward trajectory, the Price-to-Earnings (P/E) ratio reflects acute fluctuations driven primarily by temporary contractions in quarterly earnings performance.

Share Price Performance
A general upward trend is observed in the share price, which rose from 238.13 US$ in March 2022 to 407.83 US$ by June 2026. The growth was steady through 2022 and 2023, followed by a more pronounced acceleration starting in early 2024, despite some interim volatility in late 2024 and early 2025.
Earnings Per Share (EPS) Trends
Earnings per share remained relatively stable between 10.71 US$ and 14.92 US$ from March 2022 through December 2023. A significant decline occurred during the first half of 2024, with EPS dropping to a period low of 5.83 US$ in June 2024. A consistent recovery followed this trough, with EPS returning to double digits by March 2025 and reaching a peak of 16.17 US$ by June 2026.
Price-to-Earnings (P/E) Ratio Analysis
The P/E ratio was maintained within a moderate range of 16.18 to 23.14 from March 2022 to December 2023. A dramatic expansion occurred in the first half of 2024, peaking at 53.65 in June 2024. This spike is directly attributable to the simultaneous decline in EPS and the continued increase in share price, indicating a temporary disconnect between current earnings and market valuation. From March 2025 onward, the P/E ratio stabilized, fluctuating within a narrower band between 22.82 and 25.81 as earnings recovered to align with the higher share price.

AI Ask an analyst for more



Price to Operating Profit (P/OP)

Amgen Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 540,632,005 539,708,274 539,067,675 538,480,671 538,361,851 537,706,118 537,204,943 537,532,723 537,329,220 536,434,692 535,918,901 535,178,027 534,901,181 534,326,594 533,976,238 533,579,206 534,930,850 534,199,933
Selected Financial Data (US$)
Operating income (in millions) 3,514 2,666 2,720 2,526 2,656 1,178 2,311 2,047 1,909 991 1,271 2,021 2,684 1,921 2,230 2,660 2,176 2,500
Operating profit per share2 21.13 19.58 16.84 16.10 15.22 13.85 13.51 11.57 11.52 12.99 14.74 16.55 17.75 16.82 17.91 18.07 17.49 14.99
Share price1, 3 407.83 329.82 369.19 319.86 284.67 281.22 291.16 320.16 312.50 311.29 290.07 255.70 243.28 239.74 240.00 269.04 246.25 238.13
Valuation Ratio
P/OP ratio4 19.30 16.84 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 25.67 23.23 26.37 42.20 31.76 32.37 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57
Bristol-Myers Squibb Co. 11.30 12.42 12.20 10.25 11.07 13.65 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32
Danaher Corp. 24.54 28.93 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Eli Lilly & Co. 32.74 27.92 37.24 34.60 35.19 53.43 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49
Gilead Sciences Inc. 16.05 18.29 14.06 17.00 14.96 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78
Johnson & Johnson 24.10 21.40 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Merck & Co. Inc. 49.74 23.37 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Pfizer Inc. 10.48 10.37 10.82 10.07 9.49 11.27 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Regeneron Pharmaceuticals Inc. 19.78 19.83 22.90 18.65 15.42 16.03 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98
Thermo Fisher Scientific Inc. 26.07 22.09 24.94 28.40 23.62 21.64 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84
Vertex Pharmaceuticals Inc. 25.40 23.01 29.92 26.79 24.50 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
Operating profit per share = (Operating incomeQ2 2026 + Operating incomeQ1 2026 + Operating incomeQ4 2025 + Operating incomeQ3 2025) ÷ No. shares of common stock outstanding
= (3,514,000,000 + 2,666,000,000 + 2,720,000,000 + 2,526,000,000) ÷ 540,632,005 = 21.13

3 Closing price as at the filing date of Amgen Inc. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 407.83 ÷ 21.13 = 19.30

5 Click competitor name to see calculations.


The financial trajectory between March 2022 and June 2026 is characterized by a general appreciation in share price and a fluctuating operating profit per share, leading to significant shifts in the Price to Operating Profit (P/OP) valuation ratio.

Share Price Performance
The share price exhibited a long-term upward trend, rising from 238.13 US$ in March 2022 to 407.83 US$ by June 2026. While the growth was generally positive, periodic volatility is evident, specifically during the second half of 2024 when the price retracted from 320.16 US$ in September to 291.16 US$ in December, before resuming a strong ascent through 2025 and early 2026.
Operating Profit per Share Dynamics
Operating profit per share followed a non-linear path. After maintaining a range between 14.99 US$ and 18.07 US$ throughout 2022, a downward trend emerged, reaching a trough of 11.52 US$ in June 2024. This decline was followed by a sustained recovery period, with profit per share climbing consistently from late 2024 through June 2026, eventually peaking at 21.13 US$.
Price to Operating Profit (P/OP) Ratio Analysis
The P/OP ratio remained relatively stable between 13.40 and 15.88 during the first six quarters of the analyzed period. A sharp valuation expansion occurred between December 2023 and September 2024, with the ratio peaking at 27.68. This spike was driven by the divergence of an increasing share price and a simultaneous decline in operating profit per share. In the subsequent period, the ratio underwent a normalization process, fluctuating between 16.84 and 21.92 as operating profits recovered to better align with the higher share price.

The overall data indicates a period of valuation stress in 2024, where the market price outpaced fundamental operating earnings. However, the subsequent growth in operating profit per share through 2025 and 2026 served to stabilize the valuation ratio, supporting the higher share price levels on a more fundamental basis.

AI Ask an analyst for more



Price to Sales (P/S)

Amgen Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 540,632,005 539,708,274 539,067,675 538,480,671 538,361,851 537,706,118 537,204,943 537,532,723 537,329,220 536,434,692 535,918,901 535,178,027 534,901,181 534,326,594 533,976,238 533,579,206 534,930,850 534,199,933
Selected Financial Data (US$)
Product sales (in millions) 9,537 8,218 9,367 9,137 8,771 7,873 8,716 8,151 8,041 7,118 7,833 6,548 6,683 5,846 6,552 6,237 6,281 5,731
Sales per share2 67.07 65.76 65.20 64.06 62.25 60.96 59.62 57.94 54.98 52.54 50.21 47.89 47.33 46.63 46.45 45.95 45.99 45.74
Share price1, 3 407.83 329.82 369.19 319.86 284.67 281.22 291.16 320.16 312.50 311.29 290.07 255.70 243.28 239.74 240.00 269.04 246.25 238.13
Valuation Ratio
P/S ratio4 6.08 5.02 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 6.73 5.67 6.50 6.40 5.97 5.68 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76
Bristol-Myers Squibb Co. 2.69 2.55 2.53 1.93 1.85 2.08 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41
Danaher Corp. 5.01 5.56 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Eli Lilly & Co. 13.82 12.18 15.03 13.44 11.39 15.36 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47
Gilead Sciences Inc. 5.44 5.69 6.34 5.16 4.76 4.31 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86
Johnson & Johnson 6.38 5.65 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Merck & Co. Inc. 4.77 4.25 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Pfizer Inc. 2.27 2.38 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Regeneron Pharmaceuticals Inc. 4.89 4.82 5.71 4.83 4.17 4.36 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40
Thermo Fisher Scientific Inc. 4.58 3.86 4.34 4.87 4.05 3.73 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20
Vertex Pharmaceuticals Inc. 9.64 8.82 10.40 9.13 8.42 10.41 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
Sales per share = (Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025 + Product salesQ3 2025) ÷ No. shares of common stock outstanding
= (9,537,000,000 + 8,218,000,000 + 9,367,000,000 + 9,137,000,000) ÷ 540,632,005 = 67.07

3 Closing price as at the filing date of Amgen Inc. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 407.83 ÷ 67.07 = 6.08

5 Click competitor name to see calculations.


An analysis of the valuation metrics from March 31, 2022, to June 30, 2026, reveals a consistent growth in fundamental revenue performance contrasted with a more volatile share price trajectory, resulting in a fluctuating Price-to-Sales (P/S) ratio.

Sales per Share Growth
A sustained and linear upward trend is observed in sales per share, which grew from 45.74 US$ in March 2022 to 67.07 US$ by June 2026. This continuous increase indicates a steady expansion of revenue generation on a per-share basis throughout the entire period analyzed.
Share Price Volatility
The share price exhibited significant fluctuations, characterized by an overall upward trajectory from 238.13 US$ to a peak of 407.83 US$. Notable periods of contraction occurred in December 2022 and December 2024, followed by recovery phases and a substantial increase in valuation during the first half of 2026.
Price-to-Sales (P/S) Ratio Dynamics
The P/S ratio remained relatively range-bound between 4.57 and 6.08. A period of valuation compression is evident between March 2024 and June 2025, where the ratio declined from 5.93 to a low of 4.57, suggesting that sales growth outpaced share price appreciation during this window.
Recent Valuation Expansion
A sharp increase in the P/S ratio is observed toward the end of the period, rising from 5.02 in March 2026 to 6.08 in June 2026. This expansion was driven by a significant surge in the share price that exceeded the incremental growth in sales per share, marking the highest valuation multiple in the analyzed timeframe.

AI Ask an analyst for more



Price to Book Value (P/BV)

Amgen Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 540,632,005 539,708,274 539,067,675 538,480,671 538,361,851 537,706,118 537,204,943 537,532,723 537,329,220 536,434,692 535,918,901 535,178,027 534,901,181 534,326,594 533,976,238 533,579,206 534,930,850 534,199,933
Selected Financial Data (US$)
Stockholders’ equity (in millions) 11,688 9,190 8,658 9,619 7,428 6,207 5,877 7,527 5,925 5,022 6,232 7,656 6,781 5,348 3,661 3,653 2,419 916
Book value per share (BVPS)2 21.62 17.03 16.06 17.86 13.80 11.54 10.94 14.00 11.03 9.36 11.63 14.31 12.68 10.01 6.86 6.85 4.52 1.71
Share price1, 3 407.83 329.82 369.19 319.86 284.67 281.22 291.16 320.16 312.50 311.29 290.07 255.70 243.28 239.74 240.00 269.04 246.25 238.13
Valuation Ratio
P/BV ratio4 18.86 19.37 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 229.63 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59
Bristol-Myers Squibb Co. 5.94 6.17 6.61 5.01 5.06 5.70 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07
Danaher Corp. 2.39 2.60 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36
Eli Lilly & Co. 32.51 28.21 36.91 33.55 33.19 47.74 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75
Gilead Sciences Inc. 13.72 7.08 8.07 6.85 6.96 6.42 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91
Johnson & Johnson 7.35 6.70 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36
Merck & Co. Inc. 7.57 6.09 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44
Pfizer Inc. 1.70 1.67 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37
Regeneron Pharmaceuticals Inc. 2.40 2.29 2.62 2.22 1.98 2.09 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65
Thermo Fisher Scientific Inc. 4.03 3.36 3.62 4.18 3.46 3.24 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23
Vertex Pharmaceuticals Inc. 5.99 5.56 6.69 6.18 5.60 7.01 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2026 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 11,688,000,000 ÷ 540,632,005 = 21.62

3 Closing price as at the filing date of Amgen Inc. Quarterly or Annual Report.

4 Q2 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 407.83 ÷ 21.62 = 18.86

5 Click competitor name to see calculations.


An analysis of the valuation metrics from March 2022 through June 2026 reveals a significant compression in the Price to Book Value (P/BV) ratio, moving from an extreme premium to a more stabilized valuation level. This trend is primarily driven by a substantial increase in the underlying book value per share, which occurred alongside more moderate growth in the market share price.

Price to Book Value (P/BV) Ratio Trends
The P/BV ratio experienced a sharp decline during the first half of the analyzed period, falling from a peak of 138.87 in March 2022 to a low of 17.87 by September 2023. Following this contraction, the ratio exhibited volatility, spiking to 33.25 in March 2024 before gradually trending downward again to end at 18.86 in June 2026. This overall reduction suggests a convergence between the market's valuation of the company and its accounting equity.
Book Value Per Share (BVPS) Growth
A consistent upward trajectory in BVPS is observed, starting at 1.71 USD in March 2022 and reaching 21.62 USD by June 2026. This represents a significant expansion of the company's equity base per share. Notable accelerations in book value growth occurred between March 2022 and March 2023, and again between June 2025 and June 2026, which served as the primary catalyst for the lowering P/BV ratios.
Share Price Correlation
The share price demonstrated a general long-term increase, rising from 238.13 USD in March 2022 to 407.83 USD in June 2026. However, the rate of share price appreciation was significantly outpaced by the growth in BVPS during the initial phases of the period. Periodic fluctuations in the P/BV ratio, such as the increase observed in early 2024, correlate with temporary dips in BVPS (falling to 9.36 USD in March 2024) coinciding with rising share prices.
Valuation Stability
The final quarters of the analysis indicate a period of relative stability in the P/BV ratio, fluctuating between approximately 17.91 and 22.99. This suggests that the market valuation has reached a more sustainable equilibrium relative to the company's book value compared to the extreme volatility observed in 2022.

AI Ask an analyst for more